早期妊娠双酚类与邻苯二甲酸酯代谢物水平、母体血流动力学及妊娠期高血压疾病
基于人群的前瞻性队列研究纳入1233名孕妇,检测早孕期尿双酚类与邻苯二甲酸酯代谢物,分析其与胎盘功能标志物、孕期血压轨迹及妊娠期高血压疾病的关系。结果显示这些暴露与母体血压变化或妊娠期高血压疾病无一致关联,但与胎盘血管生成标志物及胎盘血流动力学存在亚临床的统计学显著关联。
要点
- 高分子量邻苯二甲酸酯代谢物每增加1个对数单位,早孕期sFlt-1/PlGF比值升高141.72(95%CI:29.13,373.21)。
- 双酚A每增加1个对数单位,脐动脉PI Z评分截距升高0.15 SD(95%CI:0.03,0.26),斜率下降-0.01 SD(95%CI:-0.01,-0.00)。
- 双酚A每增加1个对数单位,子宫动脉RI Z评分截距降低-1.28 SD(95%CI:-2.24,-0.33),斜率升高0.06 SD(95%CI:0.02,0.11)。
核心结论
- 在低风险人群中,早孕期双酚类与邻苯二甲酸酯代谢物与孕期血压纵向变化无关。
- 研究结果更支持早孕期双酚类与邻苯二甲酸酯代谢物与子痫前期风险相关,而非与妊娠期高血压相关。
研究设计与样本
- 基于人群的前瞻性队列研究,在1396名儿童参与产后随访测量的女性中于早孕期采集单次尿样检测双酚类与邻苯二甲酸酯代谢物浓度。
- 排除无任何血压测量或已有高血压的女性后,1233名女性纳入分析,尿样采集中位孕龄13.1周(四分位距12.1-14.5)。
主要发现
- 高分子量邻苯二甲酸酯代谢物每增加1个对数单位,早孕期sFlt-1/PlGF比值升高141.72(95%CI:29.13,373.21),该关联由mono-[(2-carboxymethyl)hexyl]phthalate驱动。
- 双酚A每增加1个对数单位,脐动脉PI Z评分截距升高0.15 SD(95%CI:0.03,0.26),斜率下降-0.01 SD(95%CI:-0.01,-0.00)。
- 双酚A每增加1个对数单位,子宫动脉RI Z评分截距降低-1.28 SD(95%CI:-2.24,-0.33),斜率升高0.06 SD(95%CI:0.02,0.11)。
- 上述关联经Bonferroni校正后仍显著。
- 早孕期双酚类或邻苯二甲酸酯代谢物与任何其他结局均无一致关联。
临床怎么用
- 原文未据此给出推荐。
局限性
- 大量潜在混杂因素信息可得,但部分为自我报告。
- 双酚类与邻苯二甲酸酯代谢物半衰期通常为24-48小时,本研究仅通过早孕期单次尿样测量。
- 在当前样本量下,研究对妊娠期高血压可检测的比值比为1.57、对子痫前期为1.78,但对这些结局进行多变量分析时把握度不足。
- 可能需要结合不同队列数据的进一步研究以增加把握度。
- 这些局限性可能导致非差异性错分,从而产生趋向无效值的偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Are early-pregnancy urinary bisphenol and phthalate metabolite concentrations associated with placental function markers, blood pressure (BP) trajectories during pregnancy and risk of gestational hypertensive disorders? SUMMARY ANSWER: Early-pregnancy bisphenols and phthalate metabolites were not consistently associated with maternal BP changes or gestational hypertensive disorders, but subclinical, statistically significant associations with placental angiogenic markers and placental hemodynamics were identified. WHAT IS KNOWN ALREADY: In vitro studies suggest that bisphenols and phthalate metabolites may disrupt early placental development and affect the risk of gestational hypertensive disorders. Previous studies investigating effects of bisphenols and phthalate metabolites on gestational hypertensive disorders reported inconsistent results and did not examine placental function or BP throughout pregnancy. STUDY DESIGN, SIZE, DURATION: In a population-based prospective cohort study, bisphenol and phthalate metabolite concentrations were measured in a spot urine sample in early pregnancy among 1396 women whose children participated in postnatal follow-up measurements. PARTICIPANTS/MATERIALS, SETTING, METHODS: After exclusion of women without any BP measurement or with pre-existing hypertension, 1233 women were included in the analysis. Urinary bisphenol and phthalate metabolite concentrations were measured in early-pregnancy [median gestational age 13.1 weeks, inter-quartile range 12.1-14.5]. Molar sums of total bisphenols and of low molecular weight phthalate, high molecular weight (HMW) phthalate, di-2-ethylhexylphthalate, and di-n-octylphthalate metabolites were calculated. Placental angiogenic markers (placental growth factor (PlGF), soluble fms-like tyrosine kinase (sFlt)-1), placental hemodynamic function measures (umbilical artery pulsatility index (PI), uterine artery resistance index (RI), notching and placental weight), and maternal BP were measured in different trimesters. Information on gestational hypertensive disorders was obtained from medical records. MAIN RESULTS AND THE ROLE OF CHANCE: Each log unit increase in HMW phthalate metabolites was associated with a 141.72 (95% CI: 29.13, 373.21) higher early pregnancy sFlt-1/PlGF ratio (range in total sample 9-900). This association was driven by mono-[(2-carboxymethyl)hexyl]phthalate. In the repeated measurements regression models, each log unit increase in bisphenol A was associated with a 0.15 SD (95% CI: 0.03, 0.26) higher intercept and -0.01 SD (95% CI: -0.01, -0.00) decreasing slope of the umbilical artery PI Z-score and a -1.28 SD (95% CI: -2.24, -0.33) lower intercept and 0.06 SD (95% CI: 0.02, 0.11) increasing slope of the uterine artery RI Z-score. These associations remained significant after Bonferroni correction. Early-pregnancy bisphenols or phthalate metabolites showed no consistent associations with any other outcome. LIMITATIONS, REASONS FOR CAUTION: Information on a large number of potential confounders was available but was partly self-reported. Bisphenols and phthalate metabolites, which typically have a half-life of 24-48 h, were measured via single spot urine samples in early-pregnancy. In addition, at the current sample size, the study was powered to detect an odds ratio of 1.57 for gestational hypertension and 1.78 for pre-eclampsia, but was underpowered to perform multivariable analyses for these outcomes. Further studies combining data from different cohorts may be necessary to increase power. These limitations are possible sources of non-differential misclassification leading to bias toward the null. WIDER IMPLICATIONS OF THE FINDINGS: Bisphenols and phthalate metabolites were not associated with longitudinal changes in BP in pregnancy in our low-risk population. The observed subclinical associations of phthalates with the sFlt-1/PlGF ratio and of bisphenol A with placental hemodynamics may contribute to adverse pregnancy outcomes. Our results are therefore more supportive of an association of early pregnancy bisphenols and phthalate metabolites with risk for pre-eclampsia than with gestational hypertension. STUDY FUNDING/COMPETING INTEREST(S): This analysis was supported by Grant (ES022972) from the National Institutes of Health, USA. The content is solely the responsibility of the authors and does not represent the official views of the National Institutes of Health. The authors report no conflicts of interest.
引用
- Philips EM, Trasande L, Kahn LG, et al. Early pregnancy bisphenol and phthalate metabolite levels, maternal hemodynamics and gestational hypertensive disorders. Hum Reprod. 2019. PMID: 30576447. doi:10.1093/humrep/dey364
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。